Jeffrey S. Wasser

Medicine · Health Sciences

24h-index3.6kcitations72works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(33), Cancer Immunotherapy and Biomarkers(27), Blood groups and transfusion(20), Lung Cancer Treatments and Mutations(13), Chronic Lymphocytic Leukemia Research(12)

Publications71 total

Supplemental Figure 2 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Table 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Data from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Figure 2 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Figure 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Figure 3 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Figure 3 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Data from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Table 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
Supplemental Figure 1 from Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
2023Open Access
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer·2022· 54 citedOpen Access
Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia
Clinical Pharmacology & Therapeutics·2021· 5 cited
Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method
Research and Practice in Thrombosis and Haemostasis·2020· 21 citedOpen Access
Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method
Blood·2020
Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States
SHILAP Revista de lepidopterología·2020Open Access
<p>Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States</p>
Clinical Epidemiology·2020· 11 citedOpen Access
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer
Clinical Cancer Research·2020· 103 citedOpen Access
Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States
Blood·2018
Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs)
Annals of Oncology·2018· 3 citedOpen Access
OA05.02 Epacadostat Plus Pembrolizumab in Patients with Non-Small Cell Lung Cancer: Phase 1/2 Results from ECHO-202/KEYNOTE-037
Journal of Thoracic Oncology·2018· 3 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Roger M. Lyons(11), David J. Kuter(10), Omid Hamid(10), Ivy Altomare(10), James B. Bussel(9), Todd M. Bauer(8), Yufan Zhao(8), Adrian C. Newland(7), David C. Smith(7), Ani Sarkis Balmanoukian(7), Emmett V. Schmidt(7), Tara C. Gangadhar(7), Janet L. Nichol(6), Anthony J. Olszanski(6), Thomas F. Gajewski(6), Karynsa Cetin(6), Vinod Pullarkat(5), Terry Gernsheimer(5), Louis M. Aledort(5), James N. George(5)